JGC
ATRS

J. Goldman & Co’s Antares Pharma, Inc. ATRS Stock Holding History

J. Goldman & Co’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-181,500
Closed -$423K – 437
2016
Q4 		$423K Sell
181,500
-78,500
-30% -$149K 0.03% 262
2016
Q3 		$437K Buy
+260,000
New +$319K 0.02% 268
2014
Q2 		– Sell
-973,572
Closed -$3.41M – 324
2014
Q1 		$3.41M Buy
973,572
+711,072
+271% +$3.15M 0.25% 125
2013
Q4 		$1.17M Buy
+262,500
New +$1.07M 0.15% 150

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

J. Goldman & Co's ATRS Position: Q1 2017 in Review

J. Goldman & Co sold out of Antares Pharma, Inc. (ATRS) in Q1 2017, closing a stake of 181,500 shares — an estimated $423K sold.

J. Goldman & Co first reported a position in ATRS in Q4 2013 and held it in 4 quarters. The position peaked at $3.41M in Q1 2014. 85 funds tracked by Wall St. Rank hold ATRS as of Q1 2017.

  • J. Goldman & Co reported no remaining Antares Pharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • J. Goldman & Co sold 181,500 Antares Pharma, Inc. shares in Q1 2017, an estimated $423K.
  • J. Goldman & Co first reported a position in Antares Pharma, Inc. in Q4 2013 and held it in 4 quarters.
  • J. Goldman & Co's Antares Pharma, Inc. position peaked at $3.41M in Q1 2014.
  • 85 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2017.

Based on J. Goldman & Co's 13F filing for Q1 2017, filed 15 May 2017.